1. Home
  2. NOTV vs MCRB Comparison

NOTV vs MCRB Comparison

Compare NOTV & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NOTV
  • MCRB
  • Stock Information
  • Founded
  • NOTV 1974
  • MCRB 2010
  • Country
  • NOTV United States
  • MCRB United States
  • Employees
  • NOTV N/A
  • MCRB N/A
  • Industry
  • NOTV Biotechnology: Pharmaceutical Preparations
  • MCRB Biotechnology: Pharmaceutical Preparations
  • Sector
  • NOTV Health Care
  • MCRB Health Care
  • Exchange
  • NOTV Nasdaq
  • MCRB Nasdaq
  • Market Cap
  • NOTV 137.5M
  • MCRB 141.9M
  • IPO Year
  • NOTV 1997
  • MCRB 2015
  • Fundamental
  • Price
  • NOTV $2.21
  • MCRB $0.70
  • Analyst Decision
  • NOTV Strong Buy
  • MCRB Hold
  • Analyst Count
  • NOTV 3
  • MCRB 5
  • Target Price
  • NOTV $5.92
  • MCRB $4.00
  • AVG Volume (30 Days)
  • NOTV 552.5K
  • MCRB 862.7K
  • Earning Date
  • NOTV 05-09-2025
  • MCRB 03-13-2025
  • Dividend Yield
  • NOTV N/A
  • MCRB N/A
  • EPS Growth
  • NOTV N/A
  • MCRB N/A
  • EPS
  • NOTV N/A
  • MCRB 0.00
  • Revenue
  • NOTV $475,114,000.00
  • MCRB N/A
  • Revenue This Year
  • NOTV $6.37
  • MCRB N/A
  • Revenue Next Year
  • NOTV $5.74
  • MCRB N/A
  • P/E Ratio
  • NOTV N/A
  • MCRB $798.74
  • Revenue Growth
  • NOTV N/A
  • MCRB N/A
  • 52 Week Low
  • NOTV $1.23
  • MCRB $0.54
  • 52 Week High
  • NOTV $11.20
  • MCRB $1.53
  • Technical
  • Relative Strength Index (RSI)
  • NOTV 35.56
  • MCRB 44.30
  • Support Level
  • NOTV $2.72
  • MCRB $0.69
  • Resistance Level
  • NOTV $3.35
  • MCRB $0.76
  • Average True Range (ATR)
  • NOTV 0.31
  • MCRB 0.05
  • MACD
  • NOTV -0.03
  • MCRB 0.00
  • Stochastic Oscillator
  • NOTV 16.79
  • MCRB 42.13

About NOTV Inotiv Inc.

Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.

About MCRB Seres Therapeutics Inc.

Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

Share on Social Networks: